Product Data Sheet

BMS 309403



Cat. No.:	B7794
CAS No.:	300657-03-8
Formula:	C31H26N2O3
M.Wt:	474.55
Synonyms:	
Target:	Metabolism
Pathway:	Lipid Metabolism
Storage:	Store at -20°C

Solvent & Solubility

In Vitro

≥18.15mg/mL in DMSO

Preparing Stock Solutions

Concentration \ Solvent \ Mass	1mg	5mg	10mg
1 mM	2.1073 mL	10.5363 mL	21.0726 mL
5 mM	0.4215 mL	2.1073 mL	4.2145 mL
10 mM	0.2107 mL	1.0536 mL	2.1073 mL

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

Shortsummary	FABP4 inhibitor,potent and selective
IC_{50} & Target	

In Vitro

Cell Viability Assay

Cell Line:	α P2+/+ and αP2-/- THP-1 monocytic leukaemia cell line
Preparation method:	The solubility of this compound in DMSO is >18.15mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.
Reacting conditions:	1-25 μM
Applications:	Treatment with BMS309403 significantly decreased MCP-1 production from

		THP-1 macrophages in a dose- and time-dependent manner.
In Vivo	**Animal experiment**	
	Animal models:	Male Apoe-/- mice in the C57BL/6J background
	Dosage form:	oral gavage, 15 mg/kg/d, 6 weeks
	Applications:	BMS-309403 significantly reduced the extent of atherosclerotic lesion area in the proximal aorta in both the early and late intervention studies.
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

Product Citations

1. Liu G, Wang K, et al. "The natural compound GL22, isolated from Ganoderma mushrooms, suppresses tumor growth by altering lipid metabolism and triggering cell death." Cell Death Dis. 2018 Jun 7;9(6):689.PMID:29880886
2. Gao DD, Dou HX, et al. "From hit to lead: Structure-based discovery ofnaphthalene-1-sulfonamide derivatives as potent and selective inhibitors of fatty acid binding protein 4." Eur J Med Chem. 2018 Jun 25;154:44-59.PMID:29775936

See more customer validations on www.apexbt.com.

References

[1]. Furuhashi M, Tuncman G, Grgün C Z, et al. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2[J]. Nature, 2007, 447(7147): 959.

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

APExBIO Technology
www.apexbt.com
7505 Fannin street, Suite 410, Houston, TX 77054.